Journal of Clinical Endocrinology & Metabolism, Vol 42, 222-229, Copyright © 1976 by Endocrine Society

ARTICLES

Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests

JD Brunzell, RP Robertson, RL Lerner, WR Hazzard, JW Ensinck, EL Bierman and D Porte Jr

Insulin secretion and glucose disappearance rate were measured in 66 subjects with a wide range of fasting plasma glucose levels. The acute insulin response was present in subjects with fasting glucose levels below 115 mg/dl but was absent above this level. The glucose disappearance rate related to the relative acute insulin response in subjects with fasting glucose below 115 mg/dl and to total insulin response when fasting glucose levels were above 115 mg/dl. A calculated glucose disappearance rate of 1.06 per cent per minute was found when the acute isulin response was zero. All subjects with fasting glucose levels greater than 115 mg/dl had glucose disappearance rates greater than 1.06. These studies support 1) epidemiological data indicating 115 mg/dl as an upper limit of normal for fasting plasma glucose levels and 1.0 per cent per minute as a lower limit of normal for the glucose disappearance rate, and 2) evidence for an important role for the acute insulin response in the determination of glucose disappearance rates during intravenous glucose tolerance tests.

This article has been cited by other articles:

				M. J. Franz Themed Review: Lifestyle Interventions Across the Continuum of Type 2 Diabetes: Reducing the Risks of Diabetes American Journal of Lifestyle Medicine, October 1, 2007; 1(5): 327 - 334. [Abstract] [PDF]

				R. P. Robertson Estimation of {beta}-Cell Mass by Metabolic Tests: Necessary, but How Sufficient? Diabetes, October 1, 2007; 56(10): 2420 - 2424. [Abstract] [Full Text] [PDF]

				M. R. Rickels, M. Kamoun, J. Kearns, J. F. Markmann, and A. Naji Evidence for Allograft Rejection in an Islet Transplant Recipient and Effect on {beta}-Cell Secretory Capacity J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2410 - 2414. [Abstract] [Full Text] [PDF]

				L. Blonde Easing the Transition to Insulin Therapy in People With Type 2 Diabetes The Diabetes Educator, July 1, 2007; 33(Supplement_7): 232S - 240S. [Full Text] [PDF]

				B. L. Wajchenberg {beta}-Cell Failure in Diabetes and Preservation by Clinical Treatment Endocr. Rev., April 1, 2007; 28(2): 187 - 218. [Abstract] [Full Text] [PDF]

				G. Bock, C. Dalla Man, M. Campioni, E. Chittilapilly, R. Basu, G. Toffolo, C. Cobelli, and R. Rizza Effects of Nonglucose Nutrients on Insulin Secretion and Action in People With Pre-Diabetes Diabetes, April 1, 2007; 56(4): 1113 - 1119. [Abstract] [Full Text] [PDF]

				B. Ahren Insulin Secretion and Insulin Sensitivity in Relation to Fasting Glucose in Healthy Subjects Diabetes Care, March 1, 2007; 30(3): 644 - 648. [Abstract] [Full Text] [PDF]

				S. N. Davis and S. M. Renda Treating to Target in Type 2 Diabetes: A Case Presentation. The Diabetes Educator, June 1, 2006; 32(Supplement_4): 137S - 145S. [Full Text] [PDF]

				J. E. Shaw, P. Z. Zimmet, and K. G. M.M. Alberti Point: Impaired Fasting Glucose: The Case for the New American Diabetes Association Criterion Diabetes Care, May 1, 2006; 29(5): 1170 - 1172. [Full Text] [PDF]

				K. M. Utzschneider, R. L. Prigeon, D. B. Carr, R. L. Hull, J. Tong, J. B. Shofer, B. M. Retzlaff, R. H. Knopp, and S. E. Kahn Impact of Differences in Fasting Glucose and Glucose Tolerance on the Hyperbolic Relationship Between Insulin Sensitivity and Insulin Responses Diabetes Care, February 1, 2006; 29(2): 356 - 362. [Abstract] [Full Text] [PDF]

				J.-C. Henquin, M. Nenquin, P. Stiernet, and B. Ahren In Vivo and In Vitro Glucose-Induced Biphasic Insulin Secretion in the Mouse: Pattern and Role of Cytoplasmic Ca2+ and Amplification Signals in {beta}-Cells Diabetes, February 1, 2006; 55(2): 441 - 451. [Abstract] [Full Text] [PDF]

				F. Fehse, M. Trautmann, J. J. Holst, A. E. Halseth, N. Nanayakkara, L. L. Nielsen, M. S. Fineman, D. D. Kim, and M. A. Nauck Exenatide Augments First- and Second-Phase Insulin Secretion in Response to Intravenous Glucose in Subjects with Type 2 Diabetes J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 5991 - 5997. [Abstract] [Full Text] [PDF]

				C. Kjorholt, M. C. Akerfeldt, T. J. Biden, and D. R. Laybutt Chronic Hyperglycemia, Independent of Plasma Lipid Levels, Is Sufficient for the Loss of {beta}-Cell Differentiation and Secretory Function in the db/db Mouse Model of Diabetes Diabetes, September 1, 2005; 54(9): 2755 - 2763. [Abstract] [Full Text] [PDF]

				L. S. Cozma, S. D. Luzio, G. J. Dunseath, P. M. Underwood, and D. R. Owens {beta}-Cell Response During a Meal Test: A comparative study of incremental doses of repaglinide in type 2 diabetic patients Diabetes Care, May 1, 2005; 28(5): 1001 - 1007. [Abstract] [Full Text] [PDF]

				M. O. Larsen, C. B. Juhl, N. Porksen, C. F. Gotfredsen, R. D. Carr, U. Ribel, M. Wilken, and B. Rolin {beta}-Cell function and islet morphology in normal, obese, and obese {beta}-cell mass-reduced Gottingen minipigs Am J Physiol Endocrinol Metab, February 1, 2005; 288(2): E412 - E421. [Abstract] [Full Text] [PDF]

				M. R. Rickels, M. H. Schutta, J. F. Markmann, C. F. Barker, A. Naji, and K. L. Teff {beta}-Cell Function Following Human Islet Transplantation for Type 1 Diabetes Diabetes, January 1, 2005; 54(1): 100 - 106. [Abstract] [Full Text] [PDF]

				G. C. Weir and S. Bonner-Weir Five Stages of Evolving Beta-Cell Dysfunction During Progression to Diabetes Diabetes, December 1, 2004; 53(suppl_3): S16 - S21. [Abstract] [Full Text] [PDF]

				Y. Li, W. Xu, Z. Liao, B. Yao, X. Chen, Z. Huang, G. Hu, and J. Weng Induction of Long-term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients Is Associated With Improvement of {beta}-Cell Function Diabetes Care, November 1, 2004; 27(11): 2597 - 2602. [Abstract] [Full Text] [PDF]

				A. H. Xiang, R. K. Peters, S. L. Kjos, J. Goico, C. Ochoa, A. Marroquin, S. Tan, H. N. Hodis, S. P. Azen, and T. A. Buchanan Pharmacological Treatment of Insulin Resistance at Two Different Stages in the Evolution of Type 2 Diabetes: Impact on Glucose Tolerance and {beta}-Cell Function J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2846 - 2851. [Abstract] [Full Text] [PDF]

				E. A. Ryan, S. Imes, and C. Wallace Short-Term Intensive Insulin Therapy in Newly Diagnosed Type 2 Diabetes Diabetes Care, May 1, 2004; 27(5): 1028 - 1032. [Abstract] [Full Text] [PDF]

				R. P. Robertson Consequences on {beta}-Cell Function and Reserve After Long-Term Pancreas Transplantation Diabetes, March 1, 2004; 53(3): 633 - 644. [Abstract] [Full Text] [PDF]

				A. Omer, V. F. Duvivier-Kali, W. Aschenbach, V. Tchipashvili, L. J. Goodyear, and G. C. Weir Exercise Induces Hypoglycemia in Rats With Islet Transplantation Diabetes, February 1, 2004; 53(2): 360 - 365. [Abstract] [Full Text]

				J. P. Palmer, G. A. Fleming, C. J. Greenbaum, K. C. Herold, L. D. Jansa, H. Kolb, J. M. Lachin, K. S. Polonsky, P. Pozzilli, J. S. Skyler, et al. C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve {beta}-Cell Function: Report of an ADA Workshop, 21-22 October 2001 Diabetes, January 1, 2004; 53(1): 250 - 264. [Abstract] [Full Text] [PDF]

				E. V. Polyzogopoulou, F. Kalfarentzos, A. G. Vagenakis, and T. K. Alexandrides Restoration of Euglycemia and Normal Acute Insulin Response to Glucose in Obese Subjects With Type 2 Diabetes Following Bariatric Surgery Diabetes, May 1, 2003; 52(5): 1098 - 1103. [Abstract] [Full Text] [PDF]

				D. R. Laybutt, M. Glandt, G. Xu, Y. B. Ahn, N. Trivedi, S. Bonner-Weir, and G. C. Weir Critical Reduction in beta -Cell Mass Results in Two Distinct Outcomes over Time. ADAPTATION WITH IMPAIRED GLUCOSE TOLERANCE OR DECOMPENSATED DIABETES J. Biol. Chem., January 24, 2003; 278(5): 2997 - 3005. [Abstract] [Full Text] [PDF]

				Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Diabetes Care, January 1, 2003; 26(90001): s5 - 20. [Full Text] [PDF]

				Z. T. Bloomgarden Treatment of Type 2 Diabetes: The American Association of Clinical Endocrinologists Meeting, May 2002 Diabetes Care, September 1, 2002; 25(9): 1644 - 1649. [Full Text] [PDF]

				T. A. Buchanan, A. H. Xiang, R. K. Peters, S. L. Kjos, A. Marroquin, J. Goico, C. Ochoa, S. Tan, K. Berkowitz, H. N. Hodis, et al. Preservation of Pancreatic {beta}-Cell Function and Prevention of Type 2 Diabetes by Pharmacological Treatment of Insulin Resistance in High-Risk Hispanic Women Diabetes, September 1, 2002; 51(9): 2796 - 2803. [Abstract] [Full Text] [PDF]

				D. R. Laybutt, A. Sharma, D. C. Sgroi, J. Gaudet, S. Bonner-Weir, and G. C. Weir Genetic Regulation of Metabolic Pathways in beta -Cells Disrupted by Hyperglycemia J. Biol. Chem., March 22, 2002; 277(13): 10912 - 10921. [Abstract] [Full Text] [PDF]

				O. Schmitz, S. Lund, P. H. Andersen, M. Jonler, and N. Porksen Optimizing Insulin Secretagogue Therapy in Patients With Type 2 Diabetes: A randomized double-blind study with repaglinide Diabetes Care, February 1, 2002; 25(2): 342 - 346. [Abstract] [Full Text] [PDF]

				S. Del Prato, P. Marchetti, and R. C. Bonadonna Phasic Insulin Release and Metabolic Regulation in Type 2 Diabetes Diabetes, February 1, 2002; 51(90001): S109 - 116. [Abstract] [Full Text] [PDF]

				J. E. Gerich Is Reduced First-Phase Insulin Release the Earliest Detectable Abnormality in Individuals Destined to Develop Type 2 Diabetes? Diabetes, February 1, 2002; 51(90001): S117 - 121. [Abstract] [Full Text] [PDF]

				S. E. Kahn, B. Montgomery, W. Howell, M. Ligueros-Saylan, C.-H. Hsu, D. Devineni, J. F. McLeod, A. Horowitz, and J. E. Foley Importance of Early Phase Insulin Secretion to Intravenous Glucose Tolerance in Subjects with Type 2 Diabetes Mellitus J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5824 - 5829. [Abstract] [Full Text] [PDF]

				S. E. Kahn The Importance of {beta}-Cell Failure in the Development and Progression of Type 2 Diabetes J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4047 - 4058. [Full Text] [PDF]

				J. R. Singleton, A. G. Smith, and M. B. Bromberg Increased Prevalence of Impaired Glucose Tolerance in Patients With Painful Sensory Neuropathy Diabetes Care, August 1, 2001; 24(8): 1448 - 1453. [Abstract] [Full Text] [PDF]

				P. A. Hollander, S. L. Schwartz, M. R. Gatlin, S. J. Haas, H. Zheng, J. E. Foley, and B. E. Dunning Importance of Early Insulin Secretion: Comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes Diabetes Care, June 1, 2001; 24(6): 983 - 988. [Abstract] [Full Text]

				E. A. Ryan, J. R.T. Lakey, R. V. Rajotte, G. S. Korbutt, T. Kin, S. Imes, A. Rabinovitch, J. F. Elliott, D. Bigam, N. M. Kneteman, et al. Clinical Outcomes and Insulin Secretion After Islet Transplantation With the Edmonton Protocol Diabetes, April 1, 2001; 50(4): 710 - 719. [Abstract] [Full Text]

				C. E. Gleason, M. Gonzalez, J. S. Harmon, and R. P. Robertson Determinants of glucose toxicity and its reversibility in the pancreatic islet beta -cell line, HIT-T15 Am J Physiol Endocrinol Metab, November 1, 2000; 279(5): E997 - E1002. [Abstract] [Full Text] [PDF]

				B. C. HANSEN The Metabolic Syndrome X Ann. N.Y. Acad. Sci., November 18, 1999; 892(1): 1 - 24. [Full Text] [PDF]

				M. E. Røder, D. Porte Jr., R. S. Schwartz, and S. E. Kahn Disproportionately Elevated Proinsulin Levels Reflect the Degree of Impaired B Cell Secretory Capacity in Patients with Noninsulin-Dependent Diabetes Mellitus J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 604 - 608. [Abstract] [Full Text]

				N. Porksen, B. Nyholm, J. D. Veldhuis, P. C. Butler, and O. Schmitz In humans at least 75% of insulin secretion arises from punctuated insulin secretory bursts Am J Physiol Endocrinol Metab, November 1, 1997; 273(5): E908 - E914. [Abstract] [Full Text] [PDF]

				J. Meyer, J. Sturis, M. Katschinski, R. Arnold, B. Goke, and M. M. Byrne Acute hyperglycemia alters the ability of the normal beta -cell to sense and respond to glucose Am J Physiol Endocrinol Metab, April 1, 2002; 282(4): E917 - E922. [Abstract] [Full Text] [PDF]